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ABSTRACT
CONTEXT AND OBJECTIVES: Assessment of central blood pressure (BP) has grown substantially over re-
cent years because evidence has shown that central BP is more relevant to cardiovascular outcomes than 
peripheral BP. Thus, different classes of antihypertensive drugs have different effects on central BP despite 
similar reductions in brachial BP. The aim of this study was to investigate the effect of nebivolol, a β-blocker 
with vasodilator properties, on the biochemical and hemodynamic parameters of hypertensive patients. 
DESIGN AND SETTING: Experimental single cohort study conducted in the outpatient clinic of a univer-
sity hospital. 
METHODS: Twenty-six patients were recruited. All of them underwent biochemical and hemodynamic 
evaluation (BP, heart rate (HR), central BP and augmentation index) before and after 3 months of using 
nebivolol. 
RESULTS: 88.5% of the patients were male; their mean age was 49.7 ± 9.3 years and most of them were 
overweight (29.6 ± 3.1 kg/m2) with large abdominal waist (102.1 ± 7.2 cm). There were significant de-
creases in peripheral systolic BP (P = 0.0020), diastolic BP (P = 0.0049), HR (P < 0.0001) and central BP 
(129.9 ± 12.3 versus 122.3 ± 10.3 mmHg; P = 0.0083) after treatment, in comparison with the baseline 
values. There was no statistical difference in the augmentation index or in the biochemical parameters, 
from before to after the treatment. 
CONCLUSIONS: Nebivolol use seems to be associated with significant reduction of central BP in stage I 
hypertensive patients, in addition to reductions in brachial systolic and diastolic BP. 
RESUMO
CONTEXTO E OBJETIVOS: A avaliação da pressão arterial central (PAc) tem crescido substancialmente 
nos últimos anos porque as evidências mostraram que PAc central é mais relevante para os desfechos 
cardiovasculares do que pressão arterial (PA) periférica. Assim, diferentes classes de anti-hipertensivos têm 
efeitos diferentes sobre PAc apesar de reduções semelhantes na PA braquial. O objetivo foi investigar 
o efeito do nebivolol, β-bloqueador com propriedades vasodilatadoras, nos parâmetros bioquímicos e 
hemodinâmicos de pacientes hipertensos.
TIPO DE ESTUDO E LOCAL: Estudo de coorte única experimental realizado em ambulatório de hospital 
universitário.
MÉTODOS: Todos os 26 pacientes recrutados foram submetidos à avaliação bioquímica e hemodinâmica 
(PA, frequência cardíaca, FC, PAc, augmentation index) antes e após três meses usando nebivolol.
RESULTADOS: 88,5% dos indivíduos eram do sexo masculino, com média de idade de 49,7 ± 9,3 anos, 
predominância de sobrepeso (29,6 ± 3,1 kg/m2) e aumento da cintura abdominal (102,1 ± 7,2 cm). Houve 
diminuição significativa da PA sistólica periférica (P = 0,0020) e diastólica (P = 0,0049), da FC (P < 0,0001) 
e da PAc (129,9 ± 12,3 x 122,3 ± 10,3 mmHg, P = 0,0083) após o tratamento em comparação aos valores 
basais. Não houve diferença no augmentation index, nem nos parâmetros bioquímicos antes e após o 
período de tratamento.
CONCLUSÕES: O uso de nebivolol parece estar associado à redução significativa da PAc em hipertensos 
estágio 1, além da redução da pressão sistólica e diastólica braquial.
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INTRODUCTION
Recent evidence has shown that central blood pressure (BP) is 
more relevant for predicting cardiovascular (CV) outcomes than 
peripheral pressure in the brachial artery.1-4 Since the publication 
of the Conduit Artery Function Evaluation (CAFE) study,1 the 
importance of assessments of arterial function and central blood 
pressure (BP) has increased substantially. Although brachial BP is 
a powerful predictor of CV morbidity and mortality,3,4 this mea-
surement does not reflect the pressure in the central circulation.5 
It has been shown that central BP is normally lower than periph-
eral BP, and many studies have shown a consistent relationship 
between central systolic BP and cardiovascular mortality. In addi-
tion, despite similar reductions in brachial BP, different classes of 
antihypertensive drugs have different effects on the central BP and 
arterial stiffness.6 Recent studies have shown that vasodilator anti-
hypertensive drugs,1,7,8 such as renin-angiotensin system (RAS) 
inhibitors and calcium channel blockers, have a more favorable 
effect on indices of arterial stiffness than do older β-blockers, and 
particularly atenolol.9,10 It is conceivable that newer β-blockers 
with additional vasodilation properties may have favorable effects 
on arterial stiffness, compared with atenolol. 
One such drug is nebivolol, a third-generation beta 1-selec-
tive β-blocker, which has favorable effects on carbohydrate and lipid 
metabolism, as well as on endothelial function and on oxidative stress. 
In recent studies, nebivolol was shown to improve artery stiffness to a 
greater extent than older β-blockers. It has been shown to have vaso-
dilation properties in humans and animals.11-14 Among its properties 
are its ability to increase the bioavailability of nitric oxide (with con-
sequently improvement of endothelial function), its antiproliferative 
effect and its ability to decrease oxidative stress.15,16 Because endothe-
lial dysfunction and increased arterial stiffness play an important role 
in the early atherosclerotic processes and are associated with poor 
outcomes and increased mortality, independently of blood pressure, 
the ability of nebivolol to enhance the release of endothelium-derived 
nitric oxide, and consequently improve endothelial function and arte-
rial stiffness,7,8 may have significant clinical implications for the use of 
this agent in treating hypertension and cardiovascular diseases. 
OBJECTIVE
The aim of this study was to analyze the 12-week effect of nebivo-
lol treatment on hemodynamic (BP, heart rate (HR), central BP 
and augmentation index) and biochemical parameters in stage I 
hypertensive patients without previous treatment.
METHODS
Study design, setting and sample
A total of 33 patients from our outpatient hypertension clinic who 
were interested in entering the study were initially screened for 
eligibility; among these, seven did not satisfy the inclusion/exclu-
sion criteria. Thus, the sample for participation in this single-group 
prospective cohort study was composed of 26 stage I hypertensive 
patients. Stage I hypertension was defined as systolic BP ≥ 140 and 
< 160 mmHg and/or diastolic BP ≥ 90 and < 100 mmHg. Subjects 
presenting age < 18 years, hypertensive patients treated previously, 
obesity, alcohol abuse, current corticosteroid treatment, history of 
asthma, peripheral vascular disease, chronic kidney disease, sec-
ondary hypertension, unstable angina or previous myocardial 
infarction, previous stroke, heart failure, atrioventricular block, 
bradycardia < 50 bpm, pregnancy, uncontrolled diabetes mellitus 
or insulin therapy, neoplasia, history of drug abuse or any other 
clinical conditions associated with poor prognosis were excluded.
Eligible participants visited our clinical research labora-
tory at 7:00 am after a 12-hour fast, to undertake the proto-
col procedures. Anthropometric variables were measured and 
blood was sampled for the lipid profile and routine laboratory 
parameters (hemoglobin, hematocrit, platelets, leukocytes, 
glutamic oxaloacetic and pyruvic transaminases, serum creat-
inine, glucose, urea and total bilirubin). LDL-cholesterol was 
calculated using the Friedewald formula.17 Furthermore, all 
patients underwent BP recordings and determination of cen-
tral aortic BP in the consultation office, and determination of 
the augmentation index by means of applanation tonometry 
on peripheral arteries, as described below. All the latter mea-
surements were made in a quiet room with controlled air tem-
perature (approximately 22 °C). 
Treatment with nebivolol started after confirmation of the 
inclusion criteria. The patients received nebivolol at a dose 
of 5 mg/day. Follow-up visits for BP measurements, physical 
examination and study medication dispensation were made 
every month. The study participants’ adherence to the ther-
apy administered was assessed at the follow-up visits by means 
of tablet counts. At the end of the study (three months), the 
baseline measurements were repeated for all of the 26 patients 
evaluated initially. 
Assessments
Peripheral BP at the level of the brachial artery was measured in 
the seated position after a ten-minute rest, using a mercury sphyg-
momanometer and cuffs with bladder size encircling at least 80% 
of the upper-arm circumference and covering two-thirds of the 
upper-arm length.18 Brachial BP was measured in both arms, and 
if there was a difference in BP levels between the two arms, the 
measurements in the arm with the higher BP were taken into 
account. Three BP measurements with at least a one-minute inter-
val between them were obtained, and the mean of the three mea-
surements was recorded. Phase I and V Korotkoff sounds were 
recorded for systolic BP (SBP) and diastolic BP (DBP), respectively. 
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Pulse-wave analysis
Central blood pressure and augmentation index 
Arterial pulse waveforms from the left radial artery were measured 
noninvasively by means of an automated tonometry system (HEM-
9000 AI; Omron Healthcare Co. Ltd., Kyoto, Japan), after the par-
ticipants had rested in a seated position for 10 minutes. Pulse-
wave analyses were performed at least three times and the mean 
of the measurements was calculated. The radial arterial waveforms 
from this device were used to calculate the augmentation index 
(AIx). The first systolic peak (SBP1) and the late (second) systolic 
peak (SBP2) were automatically identified using the fourth-deriv-
ative wave as the second and third zero crossing points, respec-
tively. The augmentation index (AIx) was defined as the ratio of 
the height of SBP2 to that of SBP1. The brachial BP and heart rate 
(HR) were measured simultaneously in the right brachial artery 
using an oscillometric device incorporated in the HEM-9000 AI 
device. Late systolic BP in the radial artery, as an index of central 
BP, was calculated using the following equation: rSBP2 = r-AIx.
(brachial systolic BP – brachial diastolic BP) + brachial diastolic 
BP. The HR-adjusted augmentation index (AIx(75)) was calculated 
by adjusting AIx at an inverse rate of 4.8% for each ten-beats-per-
minute increment in heart rate. All measurements were performed 
by a single examiner, after the subject had fasted for at least eight 
hours, both before and after three months of nebivolol use.19,20 
Sample-size calculation
A power analysis calculation was conducted using the site 
http://www.lee.dante.br/pesquisa/amostragem/calculo_
amostra.html. Assuming an error of 0.01 and a study power of 
80%, the calculated size of the sample required in order to reject 
the hypothesis of nullity was 23. 
Statistical analysis
Descriptive analysis was performed for qualitative variables, and 
quantitative results are presented as means ± standard deviations. 
The Wilcoxon test was used to compare quantitative variables 
before and after treatment with nebivolol, among these stage I 
hypertensive patients without previous treatment. All statistical 
analyses were performed using the Minitab 15.0 statistics soft-
ware. For all tests, a P-value < 0.05 was considered significant. 
Ethical authorization
This study was approved by the Research Ethics Committee of 
the Medical School and was registered under no. 312/2008. The 
study protocol was approved by the National Ethics Committee 
(CONEP-372/2007). Informed consent was obtained from all 
participants, in relation to both the treatment and the biochemi-
cal and hemodynamic evaluation.
RESULTS
The sample was composed of 26 patients (88.5% male) with a 
mean age of 49.7 ± 9.3 years, who were predominantly over-
weight (29.6  ±  3.1  kg/m2) and had large abdominal waist cir-
cumference (102.1 ± 7.2  cm). Significant decreases in systolic 
BP (P-value  =  0.0020) and diastolic BP (P-value = 0.0049) were 
observed during the treatment with nebivolol, and these were asso-
ciated with decreases in heart rate (P-value < 0.0001) and central BP 
(P-value = 0.0083) (Table 1). There was no difference in the AIx, with 
or without correction for heart rate, during the treatment period. 
Table 1 displays the routine biochemical characteristics and the 
pulse pressure, heart rate, SBP and DBP levels at brachial artery level 
and tonometry parameters (AIx, AIx(75) and central BP). Body mass 
index, abdominal waist measurement, fasting plasma glucose, serum 
lipids and other biochemical parameters did not differ between before 
Table 1. Comparison of hemodynamic (peripheral and central) 
and biochemical parameters before and after treatment with 
nebivolol among stage I hypertensive patients
Variable Initial
After 
treatment
P-value
Peripheral hemodynamic parameters
Brachial systolic blood 
pressure (mmHg)
137.9 ± 11.5 128.5 ± 7.7 0.0020
Brachial diastolic blood 
pressure (mmHg)
85.5 ± 9.7 78.0 ± 9.0 0.0049
Brachial pulse pressure (mmHg) 52.4 ± 9.6 50.5 ± 9.0 NS
Heart rate (bpm) 74.1 ± 8.4 64.0 ± 8.3 < 0.0001
Central tonometry parameters
Augmentation index (%) 86.7 ± 9.8 89.9 ± 11.7 NS
Augmentation index 
corrected for heart rate (%)
87.0 ± 8.5 85.4 ± 10.0 NS
rSBP2 (mmHg) 129.9 ± 12.3 122.3 ± 10.3 0.0083
Biochemical parameters
Hemoglobin (mg/dl) 15.8 ± 1.4 15.6 ± 0.9 NS
Hematocrit (%) 46.8 ± 3.6 46.6 ± 2.7 NS
Platelets (x103) 227.4 ± 40.4 216.4 ± 36.4 NS
Leukocytes (x103) 7.1 ± 1.4 7.0 ± 1.5 NS
Glutamic oxaloacetic 
transaminase (U/l)
26.2 ± 10.7 22.6 ± 6.1 NS
Glutamic pyruvic 
transaminase (U/l)
40.8 ± 33.5 33.7 ± 14.9 NS
Creatinine (mg/dl) 1.2 ± 0.1 1.1 ± 0.2 NS
Glucose (mg/dl) 96.3 ± 14.1 94.5 ± 12.0 NS
Potassium (mEq/l) 4.3 ± 0.4 4.2 ± 0.4 NS
Total cholesterol (mg/dl) 237.3 ± 49.1 222.8 ± 39.1 NS
HDL-cholesterol (mg/dl) 59.3 ± 25.7 56.5 ± 39.1 NS
LDL-cholesterol (mg/dl) 129.1 ± 31.5 121.7 ± 29.3 NS
Triglycerides (mg/dl) 244.4 ± 232.1 219.7 ± 128.3 NS
Urea (mg/dl) 35.5 ± 9.1 40.0 ± 14.5 NS
Total bilirubin (mg/dl) 0.9 ± 0.5 0.8 ± 0.3 NS
rSBP2 = Late systolic blood pressure in the radial artery (= central blood 
pressure); NS = non-significant (P > 0.05).
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and after treatment. Figure 1 shows a comparison of hemodynamic 
parameters (peripheral and central) between the basal and the fol-
low-up evaluations among the patients treated with nebivolol. In this 
study, nebivolol significantly reduced brachial BP and central BP, even 
though the AIx and biochemical parameters remaining unchanged. 
DISCUSSION
In the present study, we examined the 12-week effect of nebivolol 
on biochemical and tonometry parameters among stage I hyper-
tensive patients without previous treatment. To our knowledge, 
this is the first study on Brazilian individuals to evaluate the benefi-
cial effects of nebivolol on the hemodynamic profile, and it showed 
worthwhile reductions in peripheral and central blood pressure.
This study investigated in detail the potential effects of 
nebivolol, a beta-1 selective beta-blocker, on aortic stiffness, wave 
reflections and central hemodynamic parameters in patients with 
mild hypertension that had never been treated. In this study, 
nebivolol significantly reduced brachial and central BP, even 
though the AIx remained unchanged. 
Brachial BP measurement is considered to be the best 
method for screening for and diagnosing clinical hyperten-
sion. However, over recent years, assessment of CV risk in sub-
jects with hypertension has led to development of more sophis-
ticated methods of BP measurement, such as central BP.21 
Currently, several arguments suggest that central BP is more 
relevant than peripheral (brachial) BP for determining CV risk 
assessments.19,21,22 The pressure wave generated by the left ven-
tricle travels down the arterial tree and then is reflected at any 
discontinuity of the arterial wall, especially multiple-resistance 
arterioles and their bifurcations. Thus, the pressure waveform 
recorded at any site of the arterial tree is the sum of a forward 
travelling waveform generated by left ventricular ejection and 
a backward travelling wave, reflected at peripheral sites.21,22 As a 
consequence of transmission of the pressure wave and reflec-
tions, SBP and pulse pressure (PP) are amplified by as much 
as 10-15 mmHg when moving from the aorta to the brachial 
artery. This phenomenon, which is not taken into consideration 
in published clinical guidelines, has three major consequences, 
Figure 1. Comparison of systolic blood pressure, diastolic blood pressure, central systolic blood pressure and augmentation index before 
and after treatment with nebivolol in stage I hypertensive patients. 
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which relate to CV complications of hypertension, the choice of 
antihypertensive drugs and HR regulation. 
Regarding CV complications, when large-conduit arter-
ies are healthy and compliant (young individuals), the reflected 
wave merges with the incident wave in the proximal aorta mostly 
during diastole, thereby augmenting aortic DBP and supporting 
coronary perfusion. In contrast, when the arteries are stiff (old 
individuals), wave travel is faster and the reflected wave merges 
earlier with the incident wave, thus augmenting aortic systolic 
rather than diastolic pressure. As a result, left ventricular after-
load is increased and coronary filling is compromised. This 
pathophysiological mechanism supports the idea that central BP 
is superior to peripheral BP for predicting CV risk and that it acts 
on CV risk independently of atherosclerosis and other traditional 
CV risk factors.19,21,22 
The choice of drug treatment for hypertension is also influ-
enced by wave reflections: both by their amplitude (i.e. the pro-
portion of the incident wave which is reflected) and by their tim-
ing. Acutely, vasodilator drugs reduce the amplitude of wave 
reflections and hence SBP.21 This situation is observed typically 
with nitrates, but may also occur with SRA inhibitors or calcium 
channel blockers. With the presence of chronic hypertension, 
arterial and arteriolar remodeling modifies the baseline char-
acteristics (geometry, distensibility and structure) of reflection 
sites, particularly at the arteriolar level. Under drug treatment, 
central SBP will be consistently reduced if vascular remodeling 
and reflection coefficients are adequately corrected (by means of 
SRA or calcium channel blockade), but will remain elevated if the 
structures of the microvasculature and the reflection coefficients 
remain poorly modified despite drug treatment (β-blockers).21 
It is well accepted that calcium channel blockers and drugs 
acting on the RAS improve endothelial function and arterial stiff-
ness.22-24 On the contrary, β-blockers have failed to show positive 
effects on vascular function and central hemodynamic parame-
ters.1,25,26 For this reason, recent studies have questioned whether 
β-blockers are still an appropriate therapy for uncomplicated 
hypertension.1,25,27 Since β-blockers are a heterogeneous class of 
drugs with different pharmacological and physiological prop-
erties, it may not be possible to extrapolate the results gathered 
from these studies using atenolol, to other drugs of the same class. 
It has been well demonstrated that regardless of similar reduc-
tions in brachial BP, there are several differences between the cur-
rently available β-blockers. 
Our results, along with other recent findings, support the 
conclusion that nebivolol has vascular effects that are more 
favorable than those of first and second-generation β-blockers. 
In a double-blind randomized study comparing nebivolol and 
metoprolol, Kampus et al.8 demonstrated that there was a sig-
nificant reduction in brachial BP with a significant reduction in 
central BP only in the nebivolol group. In untreated hypertensive 
patients randomized to receive nebivolol or atenolol, Mahmud 
et al. observed a significant reduction in the brachial BP and pulse 
wave velocity associated with a significant reduction in AIx in the 
nebivolol group.7 Polónia et al. showed that for similar brachial 
BP and aortic stiffness, treatment with nebivolol was associated 
with lower central systolic BP than treatment with atenolol.6 On 
the other hand, Vitale et al. showed that nebivolol was not infe-
rior to the angiotensin-receptor blocker irbesartan for improving 
endothelial function, arterial stiffness and central hemodynamic 
parameters in uncomplicated hypertensive patients.28
Studies on Caucasian and African-American subjects have 
suggested that the less effective central blood pressure control 
and consequently lower cardiovascular protection with older 
β-blockers may be due to an adverse effect from heart rate 
lowering on arterial wave reflection.29 Because of the vasodi-
lator effect, the reduction in heart rate with nebivolol is lower 
than with other β-blockers, which leads to decreased wave 
reflection and improvement in arterial stiffness.30 Peripheral 
vasodilation also may contribute towards reducing the cardiac 
afterload, and towards reverting adverse arterial remodeling. 
Moreover, arterial stiffness is linked to endothelial dysfunc-
tion and reduced bioavailability of nitric oxide,11 a phenom-
enon that can be reduced with drugs that increase nitric oxide 
production, such as nebivolol. Our findings would support 
this mechanism and would explain the decrease in central 
aortic pressure observed in this study.
The present study had several limitations. These included 
the duration of follow-up, lack of a control group and the study 
design. If the patients had been followed for a longer time, per-
haps we would have observed changes in the AIx. The lack of 
a comparison group, in our viewpoint, was the main limitation 
of this study. The randomised, placebo-controlled, and double 
blind trial represents the gold standard in evidence based medi-
cine. However, this does not invalidate the significant results of 
central BP reduction after 12 weeks of treatment with nebivo-
lol. Although brachial BP remains the principal tool used for the 
clinical diagnosis and monitoring of hypertension, there is an 
increasing body of evidence demonstrating that central BP mea-
surement may be a better prognostic marker for hypertension. 
Moreover, recent evidence suggests that some antihyper-
tensive drugs can influence central BP more consistently than 
peripheral BP. This is especially true for agents acting on the 
RAS or calcium channel blockade, as well as newer β-blockers. 
Nevertheless, large prospective studies aiming to compare the 
predictive value of peripheral and central BP in the general pop-
ulation, as well as studies comparing the effectiveness of hyper-
tension management based on peripheral BP measurements, 
compared with central BP measurements, are needed before 
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algorithms based on central BP can be recommended for clini-
cal practice.
CONCLUSIONS
In summary, nebivolol presents a favorable effect as an antihyper-
tensive drug with possible additional capacity to improve arterial 
stiffness by reducing central BP, a characteristic not exhibited by 
other β-blockers.
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